Login
$BAX
$25.54 +$0.00 (0.0%) After hours

$BAX 8-K SEC Filings

Filed On Filing
29 Oct 2026 8-K: Results of Operations and Financial Condition; Other Events

DEERFIELD, Ill., OCT. 29, 2026 – Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2026.

19 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

We are pleased to welcome you to Baxter International Inc. (“Baxter” or the “Company”) and to confirm our verbal offer of employment, subject to formal approval by the Board of Directors of Baxter (the “Board”). This is where your purpos...

18 Aug 2026 8-K: Entry into a Material Definitive Agreement; Other Events

AMENDMENT NO. 2, dated as of August 18, 2026 (this “Amendment”), among Baxter International Inc., a Delaware corporation (the “Borrower Representative”), Baxter Healthcare SA (the “Swiss Borrower” and, together with Borrower Representati...

04 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

On July 31, 2026, Anita Zielinski notified Baxter International Inc. (the “Company”) of her decision to resign as the Company’s Interim Chief Financial Officer and Senior Vice President, Chief Accounting Officer and Controller, effective...

04 Aug 2026 8-K: Other Events

DEERFIELD, Ill., Aug. 4, 2026 - Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced that it has commenced cash tender offers (each, an “Offer” and collectively, the “Offers”) for the maximum principal amount ...

30 Jul 2026 8-K: Results of Operations and Financial Condition; Other Events

DEERFIELD, Ill., JULY 30, 2026 – Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2026.

14 Jul 2026 8-K: Regulation FD Disclosure

The following tables present our U.S. and international disaggregated net sales.

08 May 2026 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

This Baxter International Inc. Executive Severance and Change in Control Plan (the “Plan”) is intended to provide benefits to Eligible Employees of Baxter International Inc. and its subsidiaries (collectively, the “Company”), who become ...

30 Apr 2026 8-K: Results of Operations and Financial Condition; Other Events

DEERFIELD, Ill., APRIL 30, 2026 – Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2026.

19 Mar 2026 8-K: Regulation FD Disclosure

Stockholder Engagement Baxter International Inc. Spring 2026 Exhibit 99.1

16 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Joel Grade to depart as Baxter CFO; Anita Zielinski named interim CFO

12 Feb 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more

DEERFIELD, Ill., FEB. 12, 2026 – Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter of 2025.

22 Dec 2025 8-K: Other Events

On December 22, 2025 (the “Final Settlement Date”), Baxter International Inc. (the “Company”) effected the final settlement of the Company’s previously announced cash tender offers (each, a “Tender Offer” and together, the “Tender Offers...

04 Dec 2025 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more

FIRST SUPPLEMENTAL INDENTURE, dated as of December 4, 2025 (this “Supplemental Indenture”), between Baxter International Inc., a Delaware corporation (the “Company”), and U.S. Bank Trust Company, National Association, as Trustee, under t...

25 Nov 2025 8-K: Entry into a Material Definitive Agreement

AMENDMENT NO. 1, dated as of November 25, 2025 (this “Amendment”), among Baxter International Inc., a Delaware corporation (the “Borrower Representative”), Baxter Healthcare SA (the “Swiss Borrower”), Baxter World Trade SRL (the “Belgian...

19 Nov 2025 8-K: Other Events

DEERFIELD, Ill., Nov. 19, 2025 - Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced that it has increased the maximum purchase price for its $1.45 billion aggregate principal amount outstanding of 1.915% Sen...

19 Nov 2025 8-K: Other Events

DEERFIELD, Ill., Nov. 19, 2025 - Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced the commencement of tender offers, subject to the terms and conditions described below, to purchase for cash the debt secur...

12 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation

On November 5, 2025, Alok Sonig notified Baxter International Inc. (the “Company”) of his decision to resign as the Company’s Executive Vice President and Group President, Pharmaceuticals, effective as of December 1, 2025, to join a comp...

30 Oct 2025 8-K: Results of Operations and Financial Condition

DEERFIELD, Ill., OCTOBER 30, 2025 – Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2025.

21 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation

On October 16, 2025, Heather Knight notified Baxter International Inc. (the “Company”) of her decision to resign as the Company’s Executive Vice President, Chief Operating Officer (“COO”) and interim group president of Medical Products a...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support